Literature DB >> 34232105

Could concurrent biopsy and microwave ablation be reliable? Concordance between frozen section examination and final pathology in CT-guided biopsy of lung cancer.

Zhigang Wei1, Xia Yang2, Yan Feng3, Yongmei Kong1, Zhigang Yao4, Jiwei Ma4, Xin Ye1.   

Abstract

PURPOSE: Microwave ablation combined with concurrent biopsy has been used for lung cancer. Frozen section (FS) diagnosis is an important supplement for the final pathology (FP). Thus, a retrospective study was conducted to evaluate the concordance between FS examination and FP in the computed tomography (CT)-guided biopsy of lung cancer.
MATERIALS AND METHODS: Patients who underwent percutaneous transthoracic needle lung biopsies and were diagnosed using both intraoperative FS examination and FP were retrospectively enrolled. Concordance between FS findings and FP in the diagnosis of malignant lung cancer and the definitive histology types were recorded.
RESULTS: Overall, 163 patients were enrolled. The concordance rate in the diagnosis of malignant tumors was 96.3%. The definitive histology types were concordant between FS examinations and FP in 112 patients (68.7%). Lung cancers undefined with FS but diagnosed as adenocarcinoma with FP were the most common type, observed in 18 patients. The concordance in the histology type was lower for those requiring immunohistochemistry for FP diagnoses (47.3 vs. 79.6%, p < 0.000). Concordance rates differed for the different histology types diagnosed using FP (adenocarcinoma vs. squamous cell carcinoma vs. small-cell lung cancer vs. others, 76.6 vs. 56.2 vs. 69.2 vs. 0.0%, p < 0.000).
CONCLUSIONS: FS was inferior to FP in the diagnosis of definitive histology types, but had a high concordance with FP in the diagnosis of malignant lung cancer.

Entities:  

Keywords:  Biopsy; diagnostic techniques and procedures; frozen sections; histopathology; lung cancer

Year:  2021        PMID: 34232105     DOI: 10.1080/02656736.2021.1947528

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  1 in total

1.  Therapy option for early-stage lung cancer in nonsurgical patients.

Authors:  Seyer Safi; Gregor S Zimmermann
Journal:  Transl Lung Cancer Res       Date:  2022-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.